Get started
ABIONYX Pharma SAABIONYX Pharma SAABIONYX Pharma SA

ABIONYX Pharma SA

No trades
See on Supercharts
Overview
Financials News Discussions Forecast Seasonals

609 chart


Full chart

609 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪122.82 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.1310 EUR
Net income (FY)
‪−4.38 M‬ EUR
Revenue (FY)
‪4.55 M‬ EUR
Shares float
‪33.04 M‬
Beta (1Y)
−0.82

Employees


Employees (FY)
51
Change (1Y)
−10 −16.39%
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

About ABIONYX Pharma SA


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Cyrille Tupin
Website
abionyx.com
Headquarters
Balma
Founded
2005
ISIN
FR0012616852
FIGI
BBG008F939T2
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. It specializes in the development of treatment for cardiovascular and metabolic disorders. The company was founded by Jean-Louis Dasseux and William F. Brinkerhoff on March 24, 2005 and is headquartered in Balma, France.

Check out other big names from the same industry as 609.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

609 news



Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange ABIONYX Pharma SA stocks are traded under the ticker 609.
We've gathered analysts' opinions on ABIONYX Pharma SA future price: according to them, 609 price has a max estimate of 11.50 EUR and a min estimate of 10.00 EUR. Watch 609 chart and read a more detailed ABIONYX Pharma SA stock forecast: see what analysts think of ABIONYX Pharma SA and suggest that you do with its stocks.
609 reached its all-time high on Jul 31, 2015 with the price of 14.0000 EUR, and its all-time low was 0.1765 EUR and was reached on Oct 28, 2019. View more price dynamics on 609 chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track ABIONYX Pharma SA financials in yearly and quarterly reports right on TradingView.
ABIONYX Pharma SA is going to release the next earnings report on Sep 25, 2025. Keep track of upcoming events with our Earnings Calendar.
609 net income for the last half-year is ‪−2.29 M‬ EUR, while the previous report showed ‪−2.09 M‬ EUR of net income which accounts for −9.82% change. Track more ABIONYX Pharma SA financial stats to get the full picture.
No, 609 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 5, 2025, the company has 51 employees. See our rating of the largest employees — is ABIONYX Pharma SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABIONYX Pharma SA EBITDA is ‪−5.09 M‬ EUR, and current EBITDA margin is −111.93%. See more stats in ABIONYX Pharma SA financial statements.
Like other stocks, 609 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABIONYX Pharma SA stock right from TradingView charts — choose your broker and connect to your account.